Scancell
US IND for SCIB1 gives Phase II study the green lightScancell
Interim results show encouraging progressScancell
Third collaboration for AvidiMab platformScancell
Second collaboration for AvidiMab platformScancell
A sweet source of financingScancell
SCIB1 Phase II study starts in UKScancell
Ground prepared for an important periodScancell
Vulpes investment brings £3.88m in new fundsScancell
SCIB2 to use new nanoparticle formulationScancell
Phase II melanoma study with SCIB1 to start in Q219